MA52648A - Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation - Google Patents

Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation

Info

Publication number: MA52648A
Authority: MA; Morocco
Prior art keywords: compounds; pharmaceutical compositions; ppar agonists; use procedures; procedures
Prior art date: 2015-10-07

Application number

MA052648A

Other languages

English (en)

Inventor

Michael Downes

Ronald M Evans

Arthur Kluge

Bharat Lagu

Masanori Miura

Sunil Kumar Panigrahi

Michael Patane

Susanta Samajdar

Ramesh Senaiar

Taisuke Takahashi

Original Assignee

Mitobridge Inc

Salk Inst Biological Studies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-07

Filing date

2016-10-05

Publication date

2021-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-05 Application filed by Mitobridge Inc, Salk Inst Biological Studies filed Critical Mitobridge Inc

2021-10-13 Publication of MA52648A publication Critical patent/MA52648A/fr

Links

102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA052648A 2015-10-07 2016-10-05 Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation MA52648A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201562238629P	2015-10-07	2015-10-07
US201562243263P	2015-10-19	2015-10-19
US201662352348P	2016-06-20	2016-06-20

Publications (1)

Publication Number	Publication Date
MA52648A true MA52648A (fr)	2021-10-13

Family

ID=57200096

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA052098A MA52098A (fr)	2015-10-07	2016-10-05	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
MA052648A MA52648A (fr)	2015-10-07	2016-10-05	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA052098A MA52098A (fr)	2015-10-07	2016-10-05	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation

Country Status (26)

Country	Link
US (6)	US10399958B2 (fr)
EP (3)	EP3359528B1 (fr)
JP (2)	JP6657413B2 (fr)
KR (2)	KR102667385B1 (fr)
CN (3)	CN113004205B (fr)
AU (3)	AU2016333963C1 (fr)
BR (1)	BR112018006866B1 (fr)
CA (1)	CA3000431A1 (fr)
CO (1)	CO2018004473A2 (fr)
DK (1)	DK3359528T3 (fr)
EA (1)	EA037371B1 (fr)
ES (3)	ES2906379T3 (fr)
HU (1)	HUE058154T2 (fr)
IL (3)	IL258225B (fr)
JO (3)	JO3738B1 (fr)
MA (2)	MA52098A (fr)
MX (3)	MX380281B (fr)
MY (1)	MY203081A (fr)
PH (1)	PH12018500762A1 (fr)
PL (1)	PL3359528T3 (fr)
PT (1)	PT3359528T (fr)
SG (1)	SG10201906400SA (fr)
TW (3)	TWI730006B (fr)
UA (1)	UA122237C2 (fr)
WO (1)	WO2017062468A1 (fr)
ZA (4)	ZA201802029B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA122237C2 (uk) *	2015-10-07	2020-10-12	Мітобрідж, Інк.	Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування
MX380531B (es)	2016-04-13	2025-03-12	Mitobridge Inc	Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
WO2018067857A1 (fr) *	2016-10-05	2018-04-12	Mitobridge, Inc.	Méthode de traitement de lésions rénales aiguës
ES2887008T3 (es) *	2016-10-05	2021-12-21	Mitobridge Inc	Formas cristalinas y de sal de compuestos agonistas del PPAR
WO2021046081A1 (fr) *	2019-09-05	2021-03-11	Rush University Medical Center	Procédés et compositions pour le traitement de troubles de la démyélinisation
US11634387B2 (en)	2019-09-26	2023-04-25	Abionyx Pharma Sa	Compounds useful for treating liver diseases
EP4305024A1 (fr) *	2021-03-08	2024-01-17	Abionyx Pharma SA	Composés utiles pour le traitement des maladies du foie
WO2022189856A1 (fr)	2021-03-08	2022-09-15	Abionyx Pharma Sa	Composés utiles pour le traitement des maladies du foie
US20240358681A1 (en)	2021-06-02	2024-10-31	Mitobridge, Inc.	Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (fr)	2022-01-25	2023-08-03	Reneo Pharmaceuticals, Inc.	Utilisation d'agonistes ppar-delta dans le traitement d'une maladie
EP4230196A1 (fr)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Composés à utiliser dans le traitement des dystrophinopathies
WO2025207099A1 (fr)	2024-03-28	2025-10-02	Astellas Pharma Inc.	Inhibiteurs de ppar-delta pour prévenir une fibrillation auriculaire post-opératoire

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4228281A (en)	1977-09-23	1980-10-14	Ciba-Geigy Corporation	Dicarboxylic acids containing triazine rings
DE4123341A1 (de)	1991-07-15	1993-01-21	Thomae Gmbh Dr K	Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en)	1995-06-09	1995-08-02	Fujisawa Pharmaceutical Co	Benzamide derivatives
EP1159263A1 (fr)	1999-02-26	2001-12-05	Merck & Co., Inc.	Nouveaux composes de sulfonamide et utilisations correspondantes
GB9919413D0 (en)	1999-08-18	1999-10-20	Zeneca Ltd	Chemical compounds
WO2002014285A1 (fr)	2000-08-17	2002-02-21	Pfizer Limited	Imidazoles substitues utilises comme inhibiteurs tafia
RU2328483C2 (ru) *	2002-08-29	2008-07-10	Мерк Энд Ко., Инк.	Индолы, обладающие противодиабетической активностью
TW200408393A (en)	2002-10-03	2004-06-01	Ono Pharmaceutical Co	Antagonist of lysophosphatidine acid receptor
WO2004060367A1 (fr)	2002-12-30	2004-07-22	Fujisawa Pharmaceutical Co., Ltd.	Derives d'imidazole et de triazole utiles en tant qu'inhibiteurs de cox-1 selectifs
WO2005030185A2 (fr)	2003-09-26	2005-04-07	Japan Tobacco Inc.	Procede pour inhiber la production de lipoproteines restantes
CN101031541A (zh)	2004-09-06	2007-09-05	弗·哈夫曼-拉罗切有限公司	4－氨基甲基苄脒衍生物及其作为因子Ⅷa抑制剂的用途
CN101119974A (zh)	2005-02-15	2008-02-06	霍夫曼-拉罗奇有限公司	作为ppar活化剂的酰胺衍生物
KR20080042170A (ko) *	2005-09-07	2008-05-14	플렉시콘, 인코퍼레이티드	Ｐｐａｒ 활성 화합물
BRPI0707338A2 (pt)	2006-01-30	2011-05-03	Transtech Pharma Inc	derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase
WO2007110237A2 (fr)	2006-03-28	2007-10-04	Novartis Ag	Amides heterocycliques destines a une utilisation en tant que produits pharmaceutiques
NZ572268A (en)	2006-04-18	2011-09-30	Nippon Chemiphar Co	Activating agent for peroxisome proliferator activated receptor delta (ppar)
DE102006023336A1 (de)	2006-05-18	2007-11-22	Merck Patent Gmbh	1,5-Diphenyl-pyrazole II
CN101085772A (zh)	2006-06-07	2007-12-12	上海艾力斯医药科技有限公司	一类具有PPARγ激动剂活性的化合物及其应用
EP2128138A1 (fr)	2007-01-29	2009-12-02	Takeda Pharmaceutical Company Limited	Composé de pyrazole
KR20080082541A (ko)	2007-03-07	2008-09-11	동아제약주식회사	퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
JP2008285452A (ja)	2007-05-21	2008-11-27	Ono Pharmaceut Co Ltd	ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
EP2234622A4 (fr)	2007-12-28	2011-03-09	Salk Inst For Biological Studi	Méthodes améliorant les performances et le tonus musculaires
ES2607482T3 (es)	2012-08-28	2017-03-31	Koc Universitesi	Placa ósea
EP2981522A4 (fr)	2013-04-05	2016-08-31	Salk Inst For Biological Studi	Antagonistes de ppar
ES2811087T3 (es)	2013-09-09	2021-03-10	Vtv Therapeutics Llc	Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2016057322A1 (fr) *	2014-10-08	2016-04-14	Salk Institute For Biological Studies	Agonistes de ppar et leurs méthodes d'utilisation
WO2016057658A1 (fr)	2014-10-08	2016-04-14	Mitobridge, Inc.	Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
UA122237C2 (uk)	2015-10-07	2020-10-12	Мітобрідж, Інк.	Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування
MX380531B (es)	2016-04-13	2025-03-12	Mitobridge Inc	Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
ES2887008T3 (es) *	2016-10-05	2021-12-21	Mitobridge Inc	Formas cristalinas y de sal de compuestos agonistas del PPAR
WO2018067857A1 (fr)	2016-10-05	2018-04-12	Mitobridge, Inc.	Méthode de traitement de lésions rénales aiguës
WO2018125961A1 (fr) *	2016-12-30	2018-07-05	Mitobridge, Inc.	Inhibiteurs de la poly-adp-ribose polymérase (parp)

2016
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/fr active Active
- 2016-10-05 CA CA3000431A patent/CA3000431A1/fr active Pending
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/fr active Active
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/fr not_active Ceased
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/fr active Active
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-09-14 JO JOJO/P/2020/0230A patent/JOP20200230B1/ar active
- 2020-09-14 JO JOJO/P/2020/0231A patent/JOP20200231B1/ar active
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2020075939A (ja)	2020-05-21
CO2018004473A2 (es)	2018-09-20
CN113004205B (zh)	2024-07-02
JOP20200230A1 (ar)	2022-10-30
IL275387A (en)	2020-07-30
JO3738B1 (ar)	2021-01-31
ES2988059T3 (es)	2024-11-19
BR112018006866B1 (pt)	2023-11-21
MA52098A (fr)	2021-01-27
IL275392B (en)	2022-05-01
TWI730408B (zh)	2021-06-11
WO2017062468A1 (fr)	2017-04-13
JP2018534355A (ja)	2018-11-22
CN108349904A (zh)	2018-07-31
JP6866514B2 (ja)	2021-04-28
MY203081A (en)	2024-06-07
NZ740846A (en)	2024-12-20
IL258225A (en)	2018-05-31
SG10201906400SA (en)	2019-08-27
MX392524B (es)	2025-03-24
EP3770146A1 (fr)	2021-01-27
KR20210126150A (ko)	2021-10-19
DK3359528T3 (en)	2022-03-07
JOP20200230B1 (ar)	2024-04-18
US20200157074A1 (en)	2020-05-21
US20190084958A1 (en)	2019-03-21
TW202012375A (zh)	2020-04-01
ZA202003664B (en)	2022-08-31
KR102667386B1 (ko)	2024-05-21
MX2020011099A (es)	2022-05-23
US11578052B2 (en)	2023-02-14
EA037371B1 (ru)	2021-03-19
ES2906379T3 (es)	2022-04-18
AU2019283837A1 (en)	2020-01-16
US20240417383A1 (en)	2024-12-19
MX2018004295A (es)	2018-08-09
MX392523B (es)	2025-03-24
AU2019283837B2 (en)	2020-12-24
UA122237C2 (uk)	2020-10-12
EA201890776A1 (ru)	2018-09-28
US10399958B2 (en)	2019-09-03
IL275387B (en)	2021-08-31
TWI730006B (zh)	2021-06-11
CN108349904B (zh)	2021-08-31
CN113024467A (zh)	2021-06-25
US10479775B1 (en)	2019-11-19
US10906885B2 (en)	2021-02-02
ES2949852T3 (es)	2023-10-03
AU2016333963B2 (en)	2021-01-07
EP3795566A1 (fr)	2021-03-24
CN113024467B (zh)	2024-08-06
ZA202003662B (en)	2022-08-31
AU2020281069B2 (en)	2022-10-27
IL258225B (en)	2021-08-31
AU2016333963A1 (en)	2018-04-12
AU2016333963C1 (en)	2021-05-27
CN113004205A (zh)	2021-06-22
US20210253549A1 (en)	2021-08-19
JP6657413B2 (ja)	2020-03-04
CA3000431A1 (fr)	2017-04-13
TW201943705A (zh)	2019-11-16
AU2020281069A1 (en)	2021-01-07
EP3359528B1 (fr)	2022-01-12
EP3795566B1 (fr)	2023-04-19
JOP20200231A1 (ar)	2022-10-30
MX380281B (es)	2025-03-12
KR102667385B1 (ko)	2024-05-21
HK1257907A1 (zh)	2019-11-01
IL275392A (en)	2020-07-30
JOP20200231B1 (ar)	2022-03-14
EP3359528A1 (fr)	2018-08-15
EP3770146B1 (fr)	2024-07-24
PT3359528T (pt)	2022-04-07
TWI742479B (zh)	2021-10-11
KR20180095797A (ko)	2018-08-28
PH12018500762A1 (en)	2018-10-29
HUE058154T2 (hu)	2022-07-28
US20190337920A1 (en)	2019-11-07
ZA202003663B (en)	2022-08-31
WO2017062468A8 (fr)	2017-05-11
EP3770146C0 (fr)	2024-07-24
US20230373948A1 (en)	2023-11-23
PL3359528T3 (pl)	2022-05-30
TW201722919A (zh)	2017-07-01
ZA201802029B (en)	2022-01-26
BR112018006866A2 (pt)	2018-10-16
MX2020011100A (es)	2022-05-23

Publication	Publication Date	Title
MA52648A (fr)	2021-10-13	Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EP3665156A4 (fr)	2021-04-28	Composés, compositions et procédés
MA50063A (fr)	2021-04-28	Composés, compositions et procédés
EP3778607C0 (fr)	2023-08-30	Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
EP3504213A4 (fr)	2020-01-15	Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr)	2019-11-27	Composés anti-crispr et leurs procédés d'utilisation
EP3313404A4 (fr)	2019-08-07	Compositions thérapeutiques, associations et procédés d'utilisation
EP3316894A4 (fr)	2019-06-19	Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3307762A4 (fr)	2019-02-27	Variants de cas9 rapporteurs et leurs procédés d'utilisation
MA39915A (fr)	2017-03-22	Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3450460A4 (fr)	2019-12-25	Conjugué de liaison multi-spécifique, compositions pharmaceutiques associées et utilisation
EP3340988A4 (fr)	2019-05-15	Composés inhibiteurs de canaux ioniques, formulations pharmaceutiques, et utilisations
MA48942A (fr)	2020-04-08	Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3845528A4 (fr)	2022-05-11	Composés de pyrazole, compositions pharmaceutiques correspondantes et utilisation associées
EP3364984A4 (fr)	2019-09-25	Composés et compositions comprenant des oligodésoxynucléotides phosphorothioés, et procédés d'utilisation associés
EP3334719A4 (fr)	2019-02-06	Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
EP3380525A4 (fr)	2019-11-13	Formulations pharmaceutiques et leurs procédés d'utilisation
MA42527A (fr)	2021-04-07	Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
EP3383853A4 (fr)	2019-06-19	Dérivés d'homobispypéridinyle en tant qu'agonistes des oxystérols bêta, compositions et leur utilisation
EP3496768A4 (fr)	2020-04-15	Compositions antimicrobiennes et procédés d'utilisation associés.
MA46543A (fr)	2019-08-21	Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
EP3468555A4 (fr)	2020-04-01	Composés antimicrobiens et leurs procédés d'utilisation
EP3350196A4 (fr)	2019-04-03	Composés carborane et leurs procédés d'utilisation
EP3349755A4 (fr)	2019-04-24	Formulations de nicotine, leurs procédés de préparation et d'utilisation
EP3500546A4 (fr)	2020-01-08	Propenylamines et leurs procédés de préparation et d'utilisation